Keyphrases
Ruxolitinib
100%
Interferon-α (IFN-α)
100%
Myeloproliferative Neoplasms
80%
Myelofibrosis
65%
Polycythemia Vera
60%
Combination Therapy
50%
B Cells
50%
Combination Treatment
50%
Immunomodulatory
50%
Complete Hematologic Response
30%
Partial Remission
20%
Monotherapy
20%
Phase II Study
20%
JAK2V617F mutation
15%
Healthy Donors
15%
Programmed Death-ligand 1 (PD-L1)
15%
Pharmacology, Toxicology and Pharmaceutical Science
Myelofibrosis
50%
Combination Therapy
50%
Ruxolitinib
50%
Polycythemia vera
50%
Gamma Interferon
50%
Myeloproliferative Neoplasm
25%
Remission
25%
Monotherapy
16%
Adverse Event
16%
Biochemistry, Genetics and Molecular Biology
B Cell
50%
Ruxolitinib
50%
Interferon Gamma
50%
